| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | McLeod HL | |
| Evans WE | |||
| P2860 | cites work | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 |
| Systematic variation in gene expression patterns in human cancer cell lines | Q28145747 | ||
| P921 | main subject | pharmacogenomics | Q1152227 |
| P304 | page(s) | 101-121 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Pharmacogenomics: unlocking the human genome for better drug therapy | |
| P478 | volume | 41 |
| Q47149558 | A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer |
| Q46923413 | An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions |
| Q46614987 | Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients |
| Q35608800 | Antiarrhythmic drugs: past, present and future |
| Q38551666 | Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review |
| Q35065516 | Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? |
| Q37055326 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel |
| Q35553873 | Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient |
| Q35078443 | Cancer pharmacogenomics: current and future applications |
| Q37191102 | Challenge for a better combination with basic evidence |
| Q35188391 | Chemotherapy individualization. |
| Q31128049 | Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping |
| Q34612133 | Comparative genome analysis and pathway reconstruction |
| Q36335956 | Concept-based learning of personalized prescribing |
| Q36474351 | Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine |
| Q56887724 | Current Awareness on Comparative and Functional Genomics |
| Q35876954 | Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms |
| Q27318232 | Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine |
| Q37627676 | Docetaxel: its role in current and future treatments for advanced gastric cancer |
| Q36061821 | Drug bioactivation, covalent binding to target proteins and toxicity relevance |
| Q37791284 | Drug interactions in metastatic breast cancer |
| Q79768663 | Drug pathways: moving beyond single gene pharmacogenetics |
| Q40601170 | Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine |
| Q34743306 | Ethical perspectives on pharmacogenomic profiling in the drug development process |
| Q36986803 | Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping |
| Q33261407 | Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay) |
| Q57421032 | Evidence for epistatic interactions in antiepileptic drug resistance |
| Q34649031 | Formats for combinatorial synthesis: solid-phase, liquid-phase and surface |
| Q40585334 | Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study |
| Q38749453 | Gene Co-Expression Analysis Predicts Genetic Variants Associated with Drug Responsiveness in Lung Cancer |
| Q41910462 | Gene expression biomarkers of response to citalopram treatment in major depressive disorder |
| Q51988543 | Genetic association mapping under founder heterogeneity via weighted haplotype similarity analysis in candidate genes. |
| Q37702926 | Genetic diversity and medicinal drug response in eye care |
| Q74551571 | Genetic polymorphisms of adrenergic receptors |
| Q35569570 | Genetic variation and hematology: single-nucleotide polymorphisms, haplotypes, and complex disease |
| Q34743245 | Genome-based pharmacogenetics and the pharmaceutical industry |
| Q35035617 | Genomics and the prediction of xenobiotic toxicity |
| Q38192063 | Global pharmacogenomics: where is the research taking us? |
| Q34312035 | Herbal modulation of P-glycoprotein |
| Q36475069 | Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q44956846 | Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway |
| Q37998365 | Individualized medicine, health medicine, and constitutional theory in Chinese medicine |
| Q34102297 | Inducible, pharmacogenetic approaches to the study of learning and memory. |
| Q34786114 | Insights into pharmacogenomics and its impact upon immunosuppressive therapy |
| Q38689857 | Metabolomics applications in precision medicine: An oncological perspective |
| Q36811537 | Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology |
| Q34836984 | Microarrays in pharmacogenomics--advances and future promise |
| Q34670698 | Molecular aspects of pain research |
| Q36691738 | Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies |
| Q35000912 | Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy |
| Q35771333 | Neonatal exposure to drugs in breast milk |
| Q34990652 | New insights in the transcriptional activity and coregulator molecules in the arterial wall |
| Q36481129 | Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine |
| Q35746810 | Pathophysiology as a basis for understanding symptom complexes and therapeutic targets |
| Q38100809 | Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine |
| Q34581712 | Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine |
| Q38778546 | Pharmacogenetic Predictors of Response |
| Q35645901 | Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing |
| Q26739350 | Pharmacogenetic studies update in type 2 diabetes mellitus |
| Q34481324 | Pharmacogenetic tactics and strategies: implications for paediatrics |
| Q36028625 | Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy |
| Q34586812 | Pharmacogenetics of Lipid-lowering Therapies |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35976402 | Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. |
| Q37913989 | Pharmacogenetics: implications for therapy in rheumatic diseases |
| Q53807397 | Pharmacogenetics: more than skin deep. |
| Q77814090 | Pharmacogenomics and the (ir)relevance of race |
| Q28071448 | Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine |
| Q35116109 | Pharmacogenomics: implications and considerations for pharmacists |
| Q35090217 | Pharmacogenomics: marshalling the human genome to individualise drug therapy |
| Q38124254 | Pharmacometabonomics and personalized medicine |
| Q41265929 | Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria |
| Q26999391 | Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome |
| Q42151556 | Prakriti-based medicine: A step towards personalized medicine |
| Q39642852 | Privacy issues in personalized medicine. |
| Q34079045 | Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients |
| Q39570743 | Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels |
| Q33570878 | Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression |
| Q61959358 | Role of Cytochrome P450 Polymorphisms in the Development of Pulmonary Drug Toxicity |
| Q36441540 | Role of pharmacogenomics in the treatment of tuberculosis: a review |
| Q47450125 | Role of structural bioinformatics and traditional Chinese medicine databases in pharmacogenomics. |
| Q48285119 | SNP databases and pharmacogenetics: great start, but a long way to go. |
| Q36967772 | SNPs in disease gene mapping, medicinal drug development and evolution |
| Q33733501 | Screening for 392 polymorphisms in 141 pharmacogenes |
| Q40008844 | Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis |
| Q39253575 | TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells |
| Q40479885 | Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. |
| Q36996178 | Testing gene-treatment interactions in pharmacogenetic studies |
| Q39210061 | The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine |
| Q24791186 | The genome Assembly Archive: a new public resource |
| Q47342870 | The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation |
| Q36545015 | The role of drug-metabolising enzymes in clinical responses to chemotherapy |
| Q34609157 | The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics |
| Q34575544 | Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity |
| Q35615776 | Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. |
| Q43284930 | UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal). |
| Q36192684 | Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies |
| Q38107101 | Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity |
| Q35024962 | Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? |
| Q34629500 | XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia |
| Q58673700 | [Pharmacogenetics II. Research molecular methods, bioinformatics and ethical concerns] |
| Q48640226 | beta2 adrenoceptor (ADRB2) pharmacogenetics and cardiovascular phenotypes during laryngoscopy and tracheal intubation. |
Search more.